期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤分子靶向治疗药物的应用进展 被引量：7

Progress in the application of molecular targeted drugs for cancer therapy
暂未订购
导出
摘要 分子靶向治疗作为肿瘤治疗的新手段,正以其低毒、副反应和高治疗效果成为肿瘤治疗研究的热点。按作用靶点以及药物的性质,分子靶向药物可分为数类,主要包括以EGFR为靶点的药物、作用于HER2/erbB2的单克隆抗体、靶向VEGF/VEGFR的药物、以白细胞CD为靶点的单克隆抗体以及作用于多个靶点的药物。本文综述肿瘤分子靶向治疗药物的应用进展。 Molecular targeted therapy is a newly developed approach for cancer therapy.With the advantages of lower toxicity,tolerable side effects and higher performance,molecular targeted therapeutic drugs（MTTD）have become a critical focus in cancer research.According to the targets and the nature of these drugs,MTTD were divided into several classes,including the drugs targeting EGFR,the monoclonal antibodies to HER2/erbB2,the drugs targeting VEGF/VEGFR,the monoclonal antibodies to CD antigen in white cells,and multi-targeted drugs.In this review,we summarize the current status of molecular targeted anti-tumor drugs.
作者 詹琼
机构地区 复旦大学附属华山医院肿瘤科
出处 《上海医药》 CAS 2011年第12期577-581,共5页 Shanghai Medical & Pharmaceutical Journal
关键词 肿瘤 分子靶向治疗 药物 cancer molecular targeted therapy drugs
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1Cunningham D,Humblet y,Siena S,et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J].N Engl J Med,2004,351(4):337-345.
  • 2van Cutsem E,K(o)hne CH,Hitre E,et al.Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J].N Engl J Med,2009,360(14):1408-1417.
  • 3Bokeermeyer C,Bondarenko I,Makhson A,et al.Fluorouracil,leucovorin,and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer[J].J Clin Oncol,2009,27(5):663-671.
  • 4高广辉,周鑫莉,黄若凡,蒋京伟,初钊辉,梁晓华.西妥昔单抗治疗转移性结直肠癌的荟萃分析[J].肿瘤,2009,29(3):253-258. 被引量：7
  • 5Mok TS,Wu yL,Thongprasert S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957.
  • 6Wu Jy,Wu SG,yang CH,et al.Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations[J].Lung Cancer,2011,72(2):205-212.
  • 7Zhang L,Shenglin X,Song X,et al.Efficacy,tolerability,and biomaker analyses from a phase III,randomized,placebo-controlled,parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804)[J].J Clin Oncol,2011,29(suppl):Abst LBA7511.
  • 8Romond EH,Perez EA,Bryant J,et al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J].N Engl J Med,2005,353(16):1673-1684.
  • 9Piccart-Gebhart MJ,Procter M,Leyland-Jones B,et al.Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer[J].N Engl J Med,2005,353(16):1659-1672.
  • 10Robert N,Leyland-Jones B,Asmar L,et al.Randomized phase III study of trastuzumab,paclitaxel,and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer[J].J Clin Oncol,2006,24(18):2786-2792.

二级参考文献23

  • 1RIVERA F, VEGA-VILLEGAS M E, LOPEZ-BREA M F, et al. Cetuximab, its clinical use and future perspectives [ J ]. Anticancer Drugs, 2008,19 (2) :99-113.
  • 2CUNNINGHAM D, HUMBLET Y, SIENA S,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[ J]. N Engl J Med, 2004, 351 (4) :337- 345.
  • 3JADAD A R, MOORE R A, CARROLL D, et al. Assessing the quality of reports of randomized clinical trials : is blinding necessary [ J ]. Control Clin Trials, 1996,17 ( 1 ) : 1-12.
  • 4CIULEANU T E, KURTEVA G, OCVIRK J, et al. A randomized, open-label CECOG phase Ⅱ study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) [ J ]. J Clin Oncol, 2008, 26 (Suppl) : abstr 4032.
  • 5ALDERSON P, GREEN S, HIGGINS J P T, et al. Cochrane reviewers' handbook 4.2.3 [ R ]. In : The Cochrane Library [ DB ]. UK: John Wiley & Sons, Ltd. , 2004:68-139.
  • 6TEJPAR S, PEETERS M, HUMBLET Y, et al. Phase Ⅰ/Ⅱ study of cetuximab dose-escalation in patients with metastatic colorectal cancer ( mCRC ) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK) , pharmacodynamic (PD) and efficacy data[ J]. J Clin Oncol, 2007, 25 ( 18 S) : abstr 4037.
  • 7HEINEMANN V, FISCHER VON WEIKERSTHAL L, VEHLING- KAISER U, et al. Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC) : A study of the German AIO CRC study group[ J]. J Clin Oncol, 2008, 26( Sup- pl) :abstr 4033.
  • 8SALTZ LB, LENZ H J, KINDLER HL, et al. Randomized phase Ⅱ trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study [ J ]. J Clin Oncol, 2007, 25 (29) : 4557-4561.
  • 9SOBRERO AF, MAUREL J, FEHRENBACHER L, et al. EPIC: Phase Ⅲ trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26(14) :2311-2319.
  • 10VAN CUTSEM E, NOWACKI M, LANG I, et al. Randomized phase Ⅲ study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial [ J ]. J Clin Oncol, 2007, 25 (16s) :4000.

共引文献6

同被引文献56

  • 1马进元,于鹏,祝毓琳,朱步东.晚期或转移性非小细胞肺癌全身治疗进展[J].中国实用内科杂志,2013,33(S1):164-166. 被引量：18
  • 2孙成法,褚容涛.整合素与肿瘤血管生成[J].肿瘤学杂志,2004,10(5):357-359. 被引量：5
  • 3储大同.肿瘤分子靶向治疗的进展及问题[J].临床肿瘤学杂志,2006,11(1):1-6. 被引量：24
  • 4Schilsky RL, Allen J, Benner J, et al. Commentary : tackling the challen- ges of developing targeted therapies for cancer[ J]. Oncologist,2010,15 (5) :484-487.
  • 5Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach [ J ]. J. Clin. Oncol, 2010,28(16) :2777 -2783.
  • 6秦叔逵;马军;游伟程.中国临床肿瘤学进展[M]北京:人民卫生出版社,2010431.
  • 7孙燕;周际昌.临床肿瘤内科手册[M]北京:人民卫生出版社,2004559.
  • 8Chen, W, Zheng, R, Baade, P D, et aL Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
  • 9Brabender J, Danenherg K D, Metzget R, et al. Epidermal growth factor receptor and HER.2-neu mRNA expression in non-small celt lung cancer is correlated with survival [J]. Clin Cancer Res, 2001, 7(7):1850-1855.
  • 10Socinski M A. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and paniturnumab[J]. Clin Cancer Res, 2007, 13(15 Pt 2):s4597-s4601.

引证文献7

二级引证文献32

上海医药
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部